Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct 31:4:85.
doi: 10.1186/1477-7525-4-85.

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company

Fabio Arpinelli  1 , Francesco Bamfi
Affiliations

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company

Fabio Arpinelli et al. Health Qual Life Outcomes. .

Abstract

The importance of the patients point of view on their health status is widely recognised. Patient-reported outcomes is a broad term encompassing a large variety of different health data reported by patients, as symptoms, functional status, Quality of Life and Health-Related Quality of Life. Measurements of Health-Related Quality of Life have been developed during many years of researches, and a lot of validated questionnaires exist. However, few attempts have been made to standardise the evaluation of instruments characteristics, no recommendations are made about interpretation on Health-Related Quality of Life results, especially regarding the clinical significance of a change leading a therapeutic approach. Moreover, the true value of Health-Related Quality of Life evaluations in clinical trials has not yet been completely defined. An important step towards a more structured and frequent use of Patient-Reported Outcomes in drug development is represented by the FDA Guidance, issued on February 2006. In our paper we aim to report some considerations on this Guidance. Our comments focus especially on the characteristics of instruments to use, the Minimal Important Difference, and the methods to calculate it. Furthermore, we present the advantages and opportunities of using the Patient-Reported Outcomes in drug development, as seen by a pharmaceutical company. The Patient-Reported Outcomes can provide additional data to make a drug more competitive than others of the same pharmacological class, and a well demonstrated positive impact on the patient' health status and daily life might allow a higher price and/or the inclusion in a reimbursement list. Applying extensively the FDA Guidance in the next trials could lead to a wider culture of subjective measurement, and to a greater consideration for the patient's opinions on his/her care. Moreover, prescribing doctors and payers could benefit from subjective information to better define the value of drugs.

PubMed Disclaimer

References

    1. Marquis P, Arnould B, Acquadro C, Roberts WM. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Development Research. 2006;67:193–201. doi: 10.1002/ddr.20077. - DOI
    1. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validità of qualità of life claims for labelling and promotion. Value Health. 1999;2:113–127. doi: 10.1046/j.1524-4733.1999.02210.x. - DOI - PubMed
    1. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to support labelling and promotional claims in the United States. Qual Life Res. 2000;9:887–900. doi: 10.1023/A:1008996223999. - DOI - PubMed
    1. Wilke RJ, Burke LB, Erickson P. Measuring treatment impact a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Contr Clin Trials. 2004;25:535–552. doi: 10.1016/j.cct.2004.09.003. - DOI - PubMed
    1. Apolone G, De Carli G, Brunetti M, Garattini S. Health-Related Qualità of Life and Regulatory Issues. Pharmacoeconomics. 2001;19:187–195. doi: 10.2165/00019053-200119020-00005. - DOI - PubMed